Molecular Type 2 Diabetes Biomarker Identified
|
By LabMedica International staff writers Posted on 23 Feb 2016 |

Image: The HiScan SQ scanner (Photo courtesy of Illumina).
Type 2 diabetes mellitus (DM) is an established risk factor for a wide range of vascular diseases, including ischemic stroke (IS) as well as heart attacks, neuropathy and blindness.
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Latest Clinical Chem. News
- Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
- Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
- First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
- Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
- Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
- Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
- Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
- New Reference Material Aims to Improve Comparability of Angiotensin II Testing
- Childhood Blood Biomarkers May Reveal Early Heart, Kidney, and Metabolic Risks
- Blood Biomarker Study Reveals Early Signals of Future Cognitive Difficulties
- International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes
- Electrical Fingerprint of Extracellular Vesicles Could Detect Pancreatic Cancer
Channels
Clinical Chemistry
view channel
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read moreMicrobiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read moreTechnology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







